Ovid Therapeutics is expecting to have data from a Phase 2 trial testing OV101Â (gaboxadol)Â in teenagers and…
Articles by Joana Carvalho, PhD
A new animal model of fragile X syndrome suggests that a short time window very early in life is…
Genetic screening for fragile X syndrome should be available to all pregnant women and to those considering having a…
Derivatives of an Alzheimer’s disease precursor may be valuable biomarkers of disease activity in fragile X syndrome, according…
Most caregivers claim that children with fragile X syndrome (FXS) show signs of social avoidance, unresponsiveness or lethargy…
Scientists have discovered a signaling cascade in fruit flies that may be a promising therapeutic target for treating fragile X…
The presence of AGG triplets in the FMR1 gene sequence may be linked to the number of CGG repeats —…
The clinical profile of FMR1 premutation carriers — individuals who have 55 to 200 CGG repeats in their…
Posture impairment in young people carrying mutations associated with fragile X-associated tremor/ataxia syndrome may already be present before the…
OV101 (gaboxadol) shows an ability to reverse the hyperactivity, irritability, anxiety, aggression and repetitive behaviors that are characteristic…